SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-23-010143 to COMPASS Pathways plc (CMPS)

COMPASS Pathways plc
Date: Sept. 14, 2023 · CIK: 0001816590 · Accession: 0000000000-23-010143

AI Filing Summary & Sentiment

File numbers found in text: 333-274436

Date
September 14, 2023
Author
Not clearly detected
Form
UPLOAD
Company
COMPASS Pathways plc

Letter

United States securities and exchange commission logo September 14, 2023 Kabir Nath Chief Executive Officer COMPASS Pathways plc 33 Broadwick Street London W1F 0DQ United Kingdom Re:COMPASS Pathways plc Registration Statement on Form S-3 Filed September 8, 2023 File No. 333-274436 Dear Kabir Nath: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Dillon Hagius at 202-551-7967 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Benjamin Marsh

Show Raw Text
United States securities and exchange commission logo
September 14, 2023
Kabir Nath
Chief Executive Officer
COMPASS Pathways plc
33 Broadwick Street
London W1F 0DQ
United Kingdom
Re:COMPASS Pathways plc
Registration Statement on Form S-3
Filed September 8, 2023
File No. 333-274436
Dear Kabir Nath:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Dillon Hagius at 202-551-7967 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Benjamin Marsh